



UNITED STATED DEPARTMENT OF COMMERCE Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		(4/E) 0	wasningit	JII, D.C. 20231	•
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/365,241	07/30/99	BRODIN		Т	003300-581
		UM4 n Z n n n a	7	EXAMINER	
' 021839 HM12/0224 BURNS DOANE SWECKER & MATHIS				WESSENDORF,T	
P 0 B0X 140				ART UNIT	PAPER NUMBER
ALEXANDRIA	VA 22313-14	04	·	1627	7
				DATE MAILED:	02/24/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

PTO-90C (Rev. 2/95) 1- File Copy

Office Action Summary

Application No. 09/365,241

Applicant(s)

Brodin et al

Examiner

T. Wessendorf

Group Art Unit 1627



Responsive to communication(s) filed on						
☐ This action is FINAL .						
☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle35 C.D. 11, 453 O.G. 213.						
A shortened statutory period for response to this action is set to expire	period for response will cause the					
Disposition of Claim	is to a sound in a in the applicat					
☐ Claim(s)						
Of the above, claim(s)						
Claim(s)	is/are allowed.					
Claim(s)	is/are rejected.					
Claim(s)	is/are objected to.					
Claims a	re subject to restriction or election requirement.					
Application Papers						
☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-94	8.					
The drawing(s) filed on is/are objected to by the E	-xaminer.					
☐ The proposed drawing correction, filed on is ☐ approved ☐disapproved.						
☐ The specification is objected to by the Examiner.						
☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. § 119	110(0) (4)					
 ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). ☐ All ☐Some* None of the CERTIFIED copies of the priority documents have been 						
	ments have been					
☐ received.☐ received in Application No. (Series Code/Serial Number)						
□ received in Application 140. (Genes Goder General Mannes)						
*Certified copies not received:						
☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C	. § 119(e).					
Attachment(s)						
☐ Notice of References Cited, PTO-892						
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s)						
☐ Interview Summary, PTO-413						
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948						
☐ Notice of Informal Patent Application, PTO-152						
* Notice to comply Seguence						
SEE OFFICE ACTION ON THE FOLLOWING	G PAGES —					

Application/Control Number: 09/365,241

Art Unit: 1627

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). See e.g., claim 53 and page 8, lines 14-15 i.e., peptide sequence IEGR. Accordingly, this application therefore fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Page 3

Application/Control Number: 09/365,241

Art Unit: 1627

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1627.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to T. Wessendorf whose telephone number is (703) 3967. The examiner can normally be reached on Mon. to Fri. from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Donald E. Adams, Ph.D., can be reached on (703) 308-0570. The fax phone number for this Group is (703) 308-7924.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Tdw

2/22/00

T. Weundorf Portent Examiner Application No.: 21/20/24)
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

$\Delta \omega^{\prime}$	
1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
and/or unreadable form that has been filed with this application has been found to be damaged computer readable form must be submitted as required by 37 C.F.R. 1.825/db.	
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide:	
M An initial or substitute account	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry	
A statement that the content of the paper and computer and the	
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or for questions regard.	
(1.825(b) or 1.825(d). For questions regarding as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or	
For questions regarding compliance to these requirements, please contact:	
For Rules Interpretation, call (703) 308-4216 For CRF Submission Holes 1997 1997 1997 1997 1997 1997 1997 199	
For CRF Submission Help, call (703) 308-4216 For Patentin software help, call (703) 308-4212	
308-6856	
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE	
TOUR RESPONSE	